THU0700 Immunogenicity in patients switching from stable originator infliximab treatment to CT-P13: analyses across six diseases from the 52-week randomized nor-switch study

Abstract

among participants using observed variables, was used to differentiate "pain phenotypes" considering sex, body mass index (BMI), emotional problems, comorbidities, number of painful sites and knee structural damage on MRI. Results: Three pain phenotypes were identified: Class 1: high levels of emotional problems and low levels of structural damage (24%); Class 2: high levels of structural damage and low levels of emotional problems (20%); Class 3: relatively low levels of emotional problems and low levels of structural damage (56%). People within Class 1 were more likely to be female, had greater BMI, lower education level, more comorbidities, more severe knee pain and more painful sites as compared to Class 2 and Class 3. Furthermore, WOMAC pain scores and number of painful sites were consistently greater at baseline, 2.6, 5.1 and 10.7 years in Class 1 than Class 2 and Class 3 (all P<0.05).

Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab

“…Non‐inferiority was not demonstrated in any of the diagnostic subgroups, except for spondyloarthritis, although the study was not powered for specific disease evaluation . Additionally, the number of patients with TEAEs were similar across the two treatment groups (reference infliximab, 70%; CT‐P13, 68%) and the incidence of ADA (excluding patients positive at baseline) were comparable (reference infliximab, 7%; CT‐P13, 8%) …”